The closely guarded world of drug pricing is getting a public airing in a feud between two of the industry’s biggest companies. The attention drawn to rebates could hurt the profits of some very successful drugs.
WSJ.com: Markets, Wall Street Journal: Markets: Market News
Wed, 09/20/2017 - 10:57am
The closely guarded world of drug pricing is getting a public airing in a feud between two of the industry’s biggest companies. The attention drawn to rebates could hurt the profits of some very successful drugs.